Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desloratadine
Drug ID BADD_D00615
Description Desloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action. It is the active descarboethoxy metabolite of loratidine (a second generation histamine). Desloratidine has a long-lasting effect and does not cause drowsiness because it does not readily enter the central nervous system.
Indications and Usage For the relief of symptoms of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis. Desloratidine is also used for the sympomatic treatment of pruritus and urticaria (hives) associated with chronic idiopathic urticaria.
Marketing Status Prescription
ATC Code R06AX27
DrugBank ID DB00967
KEGG ID D03693
MeSH ID C121345
PubChem ID 124087
TTD Drug ID D01GBY
NDC Product Code 53104-7613; 55111-073; 75895-0099; 65691-0057; 62993-0805; 62250-619; 51001-0034; 78206-119; 50090-4794; 53104-7688; 55111-551; 68180-153; 65015-698; 62756-481; 66039-830; 42291-240; 50090-3975; 55111-360; 50090-0765; 71335-1000; 62331-019; 66577-018; 69543-107
Synonyms desloratadine | descarboethoxyloratadine | SCH 34117 | SCH-34117 | Clarinex | Neoclarityn | Aerius | descarboethoxyloratadine acetate
Chemical Information
Molecular Formula C19H19ClN2
CAS Registry Number 100643-71-8
SMILES C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dyskinesia17.01.02.006--
Dysmenorrhoea21.01.01.002--
Dyspepsia07.01.02.001--
Dysphagia07.01.06.0030.002643%
Dyspnoea22.02.01.004; 02.01.03.0020.010574%
Ear swelling04.03.01.0140.002643%Not Available
Electrocardiogram abnormal13.14.05.001--Not Available
Electrocardiogram QT prolonged13.14.05.0040.006609%
Epistaxis24.07.01.005; 22.04.03.001--
Erythema23.03.06.0010.003965%Not Available
Extrapyramidal disorder17.01.02.007--
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.0030.002643%
Fatigue08.01.01.002--
Feeling abnormal08.01.09.0140.003965%Not Available
Gait disturbance17.02.05.016; 08.01.02.0020.002643%
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Generalised tonic-clonic seizure17.12.01.0020.002643%Not Available
Hallucination19.10.02.0020.003965%
Hallucination, auditory19.10.02.0030.009252%Not Available
Headache17.14.01.0010.010574%
Heart rate increased13.14.04.0020.005287%Not Available
Hepatitis09.01.07.004--Not Available
Hyperbilirubinaemia09.01.01.003; 01.06.04.003; 14.11.01.0100.002643%Not Available
Hyperkinesia17.01.02.008--Not Available
Hypersensitivity10.01.03.0030.007930%
Hypertension24.08.02.0010.005287%
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Infection11.01.08.002--Not Available
Infection parasitic11.01.08.003--Not Available
The 2th Page    First    Pre   2 3 4 5    Next   Last    Total 5 Pages